|
|
Erratum
for
Greenberg et al., Blood 89 (6) 2079-2088.
 Previous Article | Table of Contents
Blood, Vol. 91 No. 3 (February 1), 1998:
p. 1100
ERRATUM
In the article by Greenberg et al, entitled "International Scoring
System for Evaluating Prognosis in Myelodysplastic Syndromes," which
appeared in the March 15, 1997 (Vol 89, No 6, pp 2079-2088) issue, a
correction should be noted. In the text p 2080 and in Table 1, neutropenia (absolute neutrophil count, ANC) was inadvertently and
incorrectly stated as being defined as <1,500/µL rather than <1,800/µL. The latter number (<1,800/µL) was used to define
this cytopenia for the risk scoring indicated in Table 3 and for
generating the International Prognostic Scoring System (IPSS) risk
groups. As some readers may utilize the number 1,500/µL for their
classification of neutropenia, we recalculated the impact of this error
on our own data and demonstrated that this change was clinically and statistically insignificant. If this number (1,500/µL) had been used,
only 8 patients (of 816 patients, 1%) would have needed reclassification for Survival and 7 (of 759 patients) reclassified for
AML evolution. All of the reclassified patients would have been changed
from either the Intermediate-2 or -1 categories into the Low-Risk
group, as fewer patients would have been defined as being neutropenic.
The median survival and AML evolution times and Kaplan-Meier curves
were essentially unaltered when using this changed value. Readers
should be aware of this correction and use the <1,800/µL cutpoint
for categorizing MDS patients according to the IPSS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. J. Mufti, J. M. Bennett, J. Goasguen, B. J. Bain, I. Baumann, R. Brunning, M. Cazzola, P. Fenaux, U. Germing, E. Hellstrom-Lindberg, et al.
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
Haematologica,
November 1, 2008;
93(11):
1712 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Nimer
Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q
J. Clin. Oncol.,
June 1, 2006;
24(16):
2576 - 2582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer
Clinical Issues in the Management of Patients with Myelodysplasia
Hematology,
January 1, 2006;
2006(1):
205 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Bagby, J. M. Lipton, E. M. Sloand, and C. A. Schiffer
Marrow Failure
Hematology,
January 1, 2004;
2004(1):
318 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Verburgh, R. Achten, B. Maes, A. Hagemeijer, M. Boogaerts, C. De Wolf-Peeters, and G. Verhoef
Additional Prognostic Value of Bone Marrow Histology in Patients Subclassified According to the International Prognostic Scoring System for Myelodysplastic Syndromes
J. Clin. Oncol.,
January 15, 2003;
21(2):
273 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
